In short: Pitched twice — the Unilever spin-off is the compilation's most-agreed new idea. Upslope Capital: "by far the largest ice cream company in the world (~21% share) with almost double the market share of the #2 player, Froneri… beyond [those two], the largest players hold 2% share at most." The four pillars: a defensive brand portfolio (four of the top five global brands — Magnum, Ben & Jerry's, Breyers, Cornetto, Wall's) and a "complex global frozen supply chain network"; top-line and margin gains "as an independently run business"; the Froneri comp — "EBITDA margins to ~20%… vs ~16% at MICC" and a transaction "valuing Froneri… 10-11x EBITDA"; and valuation at "~9.5x 2026E EBITDA (17x EPS) with net leverage <2.5x." He also came to it deliberately screening staples "with manageable GLP-1 risks due to lower U.S. sales concentration (Magnum is ~25% U.S.)." Aristotle (International Equity ADR) adds the distribution moat: "approximately three million freezer cabinets," "more than 30 manufacturing facilities, 200 warehouses, and over 2,000 distributors," ~80% of revenue premium at "roughly 2.5x higher per kilogram than private label," at "approximately 11x our estimate of normalized earnings." Named risks: short standalone history, GLP-1, FX and weather.
Magnum is the ice-cream business Unilever separated at the end of 2025 — Magnum, Ben & Jerry's, Cornetto, Wall's, Breyers and more. It is the largest ice-cream company in the world with about 21% of the market, nearly double the next competitor, and everyone after those two has 2% at most. Two different funds in this compilation pitched it, which makes it the sample's most-agreed new idea.
Upslope came to it while looking for food companies less exposed to weight-loss drugs, since only about a quarter of Magnum's sales are American. Their case has four parts: dominant brands plus a frozen distribution network that is genuinely hard to copy; the chance to grow faster and more profitably now that ice cream is the only thing management thinks about; a direct comparison with its private rival Froneri, which earns about 20% margins against Magnum's 16% and was recently valued at 10-11 times earnings; and a valuation of roughly 9.5 times next year's earnings before interest, tax and depreciation with modest borrowings.
Aristotle emphasises the moat instead: three million freezer cabinets in shops around the world, more than thirty factories, two hundred warehouses and two thousand distributors. Frozen distribution is capital-intensive and unforgiving, and those cabinets are also what drive impulse purchases. About 80% of sales are premium products priced roughly two and a half times private label. They put the shares at about eleven times normalised earnings.
The honest risks both note: a very short history as an independent company, uncertainty about weight-loss drugs, currency exposure and, prosaically, the weather.
Full passage: premium transcript (PDF).
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.